Title

The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants.

Journal

AIDS, 38(4)

Authors

Johnson, Leigh
Myer, Landon
Jamieson, Lise
et al.

Publication Date

2024-03-15

DOI

10.1097/QAD.0000000000003803

Peer reviewed

CONCISE COMMUNICATION

The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants

Leigh F. Johnson[a], Landon Myer[b], Lise Jamieson[c,d,e], Gesine Meyer-Rath[c,e,f], Sinead Delany-Moretlwe[g] and Dvora Joseph Davey[b,h]

Background: Pregnant and breastfeeding women (PBW) in sub-Saharan Africa have high HIV incidence rates and associated risk of vertical transmission to their infants. Oral preexposure prophylaxis (PrEP) and injectable PrEP (long-acting cabotegravir, or CAB-LA) can potentially reduce this HIV transmission, but population-level impacts are uncertain.

Methods: We extended a previously developed model of HIV and PrEP in South Africa to allow for variable PrEP duration and preference in PBW. We considered three potential scenarios for PrEP provision to PBW: oral PrEP only, CAB-LA only, and allowing oral/CAB-LA choice, with uptake and retention assumptions informed by South African data, each compared with a 'base' scenario without PrEP for PBW.

Results: Without PrEP for PBW, the model estimates 1.31 million new infections will occur between 2025 and 2035 in South African adults and children, including 100 000 in PBW, 16 800 in infants at/before birth, and 35 200 in children through breastmilk. In the oral PrEP-only scenario, these numbers would reduce by 1.2% (95% CI: 0.7–1.7%), 8.6% (4.8–12.9%), 4.0% (2.1–5.8%), and 5.3% (3.0–8.2%) respectively. In the CAB-LA-only scenario, the corresponding reductions would be 6.1% (2.9–9.6%), 41.2% (19.8–65.0%), 12.6% (6.0–19.4%), and 29.5% (13.9–46.8%), respectively, and in the oral/CAB-LA choice scenario, similar reductions would be achieved [5.6% (3.4–8.0%), 39% (23.4–55.9%), 12.4% (7.4–16.8%) and 27.6% (16.5–39.9%) respectively].

Conclusion: CAB-LA has the potential to be substantially more effective than oral PrEP in preventing HIV acquisition in PBW and vertical transmission, and can also modestly reduce HIV incidence at a population level.

AIDS 2024, **38**:589–594

[a]Centre for Infectious Disease Epidemiology and Research, [b]Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, [c]Health Economics and Epidemiology Research Office, University of Witwatersrand, Johannesburg, South Africa, [d]Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, Netherlands, [e]The South African Department of Science and Innovation/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa, [f]Department of Global Health, Boston University, Boston, MA, USA, [g]Wits RHI, University of Witwatersrand, Johannesburg, South Africa, and [h]Division of Infectious Diseases, Geffen School of Medicine, University of California Los Angeles, Los Angeles CA, USA.

Correspondence to Dr Leigh F. Johnson, Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Anzio Road, Observatory, 7925, South Africa.

Tel: +27 21 406 6981; fax: +27 21 406 6764; e-mail: Leigh.Johnson@uct.ac.za

Received: 29 August 2023; revised: 21 November 2023; accepted: 23 November 2023.

DOI:10.1097/QAD.0000000000003803

ISSN 0269-9370

Keywords: breastfeeding, HIV, mathematical model, preexposure prophylaxis, pregnant women

Introduction

Pregnant and breastfeeding women (PBW) in African countries have a relatively high HIV incidence [1], and are, therefore, an obvious group in which to promote the use of preexposure prophylaxis (PrEP). In addition, PBW who acquire HIV have a high risk of transmitting HIV to their infants, and preventing incident HIV during pregnancy/breastfeeding is, therefore, particularly important in reducing vertical transmission of HIV [1,2]. In view of this, WHO guidelines recommend oral PrEP in PBW in populations with high HIV incidence, noting that there is strong evidence of the safety of tenofovir and emtricitabine (the most commonly used oral PrEP drugs) during pregnancy and breastfeeding periods [3].

However, oral PrEP persistence and adherence are challenging for PBW in African settings. Although many women report initiating oral PrEP, few continue PrEP after the first month [4,5], and even fewer are found to have detectable levels of tenofovir consistent with moderate adherence [6,7]. Our previous modelling analyses suggested that oral PrEP could substantially reduce maternal HIV acquisition and vertical transmission in the South African setting [8], but this was based on the optimistic assumption that women would continue on PrEP throughout pregnancy and until the end of breastfeeding. These model estimates need to be revised in light of the poor persistence and adherence observed in cohorts of pregnant women initiating oral PrEP [4,7].

Long-acting injectable cabotegravir (CAB-LA) is a novel form of PrEP, which is substantially more effective than oral PrEP in preventing HIV acquisition in cis-gender women [9]. Because injections are only administered every 2 months, and there may be protection against HIV even when dosing is delayed [10], adherence is likely to be less of an impediment in achieving protective levels of drug. Our model of HIV and PrEP in South Africa has recently been extended to include CAB-LA, and we have shown CAB-LA could potentially reduce HIV incidence substantially [11]. However, in this previous analysis, we did not include scenarios with CAB-LA in pregnancy, (a) because of lack of data on safety and pharmacokinetics of CAB-LA in PBW, and (b) because South African guidelines were only recently extended to recommend oral PrEP in PBW [12]. Although safety data remain limited, preliminary results do not suggest there are likely to be required CAB-LA dose adjustments or safety concerns in PBW [13].

In the absence of PrEP for PBW, vertical transmission rates in South Africa are projected to decline to 450 per 100 000 births by 2030, well above the elimination target of less than 50 per 100 000 births [14]. This study aims to compare the predicted impact of a policy of promoting CAB-LA in South African PBW against the existing policy of offering oral PrEP to PBW, using a model that is calibrated to data from a South African cohort study of PrEP in PBW [15].

Methods

We adapted the Thembisa model, which has previously been used to model the impact of PrEP in South Africa [8,11,16]. Briefly, Thembisa is a compartmental, deterministic model of HIV, developed for South Africa. The model represents heterogeneity in HIV acquisition risk between 'high-risk' and 'low-risk' individuals (defined in terms of propensity for concurrent partners and commercial sex) as well as heterogeneity by age, sex, marital status, male circumcision status, and 'key population' status (with men who have sex with men [MSM] and female sex workers [FSWs] defined as separate risk groups). The simulated epidemic begins in 1985, and the numbers of HIV-positive individuals are updated at monthly time steps, allowing for HIV acquisition and disease progression. The model allows for women to transmit HIV to their infants either at/before birth or postnatally (through breastmilk), with both transmission risks depending on the mother's stage of HIV infection (highest during the 3-month acute phase that follows HIV acquisition) and mother's receipt of antiretroviral treatment (ART). A full description of the Thembisa model is provided elsewhere [17], and sections 1 and 2 of the Supplemental Digital Content, http://links.lww.com/QAD/D57 describe the modelling of sexual and vertical transmission of HIV.

In the 'base' scenario, the model makes provision for oral PrEP in MSM, FSWs, adolescent girls and young women (ages <25) and the balance of the sexually active population, though PrEP uptake is assumed to be much lower in the latter group (and proportional to the expected annual number of partners living with HIV). The model is parameterized using routinely reported numbers of people starting PrEP in each year [17]. For the purpose of quantifying PrEP impacts, the base scenario is defined as one in which there is no uptake of CAB-LA and no uptake of PrEP (oral or injectable) in PBW.

The model was extended to allow for differences in PrEP duration and choice of PrEP method between PBW and other women. Table 1 summarizes three possible scenarios for the promotion of PrEP to PBW: oral PrEP only, CAB-LA only, and offering women a choice of oral

Table 1. Assumed preexposure prophylaxis uptake, duration and efficacy, in pregnant and breastfeeding women.

	Scenario 1	Scenario 2	Scenario 3		Sources/notes
			PrEP choice		
	Oral only	CAB-LA Only	Oral	CAB-LA	
PrEP uptake[a]	41% (12%)	54% (20%)	20% (7%)	45% (17%)	[5] for oral PrEP, [18] for CAB-LA preference
OR for PrEP uptake in low-risk, relative to high-risk[a]	0.32 (0.15)	0.32 (0.15)	0.32 (0.15)	0.32 (0.15)	[15], based on frequency of sex with HIV-positive partners
Average PrEP duration (months)[a]	6.0 (2.0)	22.0 (5.9)	8.5 (4.2)	24.0 (6.0)	[5] for oral realistic, [19–21] for CAB-LA
Average duration of 'tail' protection (months)	1	3	1	3	Same assumption as before [11], based on [34]
Average PrEP protection (months)[a]	7.0 (2.0)	25.0 (5.9)	9.5 (4.2)	27.0 (6.0)	Sum of two previous rows
PrEP efficacy[a]	55% (10%)	95% (4%)	74% (12%)	97% (3%)	Based on 50% adherence for oral PrEP [7,35], higher efficacy for CAB-LA [9,36]
Reduction in condom use if using PrEP[a]	10% (8%)	10% (8%)	10% (8%)	10% (8%)	[37]

CAB-LA, cabotegravir (long-acting); OR, odds ratio; PrEP, preexposure prophylaxis; RR, risk ratio.
[a]For parameter values that are varied in the uncertainty analysis, the first value is the mean parameter value and the second (in brackets) is the standard deviation; a full explanation for the choice of distribution is provided in section 3 of the Supplemental Digital Content, http://links.lww.com/QAD/D57.

PrEP or CAB-LA. Uptake assumptions are based on a South African cohort study [15] in the first scenario, and on local data regarding CAB-LA preferences in the latter two scenarios [18]. Probability distributions are specified to represent uncertainty around key PrEP parameters. As studies of CAB-LA in PBW are ongoing and unpublished, assumptions about the average duration of CAB-LA use are informed by a range of South African estimates of the average duration of injectable contraceptive use [19–21]. In the 'choice' scenario, women are assumed to be more motivated to remain on and adhere to their preferred prevention method. As assumed previously, average durations of PrEP use are extended by a 'tail period' (1 month for oral PrEP, 3 months for CAB-LA) to determine the average duration of protection [11].

The model was run 1000 times in the base scenario and each of the scenarios outlined in Table 1, each time using a different combination of parameters sampled from the distributions in Table 1, combined with a randomly sampled combination of parameters from the posterior distribution of Thembisa parameters generated previously [17]. The promotion of PrEP to pregnant women is assumed to begin from mid-2025, and we calculate the reduction in HIV incidence (relative to the base scenario) over the period from mid-2025 to mid-2035. We report the mean and 95% confidence interval (CI) based on the set of 1000 model projections.

Results

In the base scenario, our model predicts that between 2025 and 2035, there will be 1.31 million (95% CI: 1.19–1.43 million) new infections in adults and children, including 100 000 (89 000–111 000) in women who are attending antenatal clinics or breastfeeding, 16 800 (15 200–18 500) cases of vertical transmission at/before birth and 35 200 (31 400–39 600) cases of vertical transmission during breastfeeding. Table S2, http://links.lww.com/QAD/D57 and Fig. 1 summarize the main model results.

In the oral PrEP-only scenario, an 8.6% (4.8–12.9%) reduction in HIV incidence is expected in PBW, relative to the base scenario. Smaller reductions are expected in the number of postnatal vertical transmissions [5.3% (3.0–8.2%)], transmissions at/before birth [4.0% (2.1–5.8)] and population-level HIV incidence [1.2% (0.7–1.7%)]. Most of the variation in impact is attributed to uncertainty in PrEP uptake ($r = 0.38$) and relative odds of PrEP uptake in low-risk women ($r = -0.34$) (Figure S4, http://links.lww.com/QAD/D57). In the CAB-LA-only scenario, greater reductions in HIV incidence are expected: 41.2% (19.8–65%) in PBW, 29.5% (13.9–46.8%) in postnatal vertical transmission, 12.6% (6.0–19.4%) in transmission at/before birth, and 6.1% (2.9–9.6%) in total HIV incidence. Most of the variation in impact is attributed to uncertainty in CAB-LA uptake and the duration of CAB-LA use (Figures S1, http://links.lww.com/QAD/D57 and S2, http://links.lww.com/QAD/D57).

In the oral PrEP/CAB-LA choice scenario, reductions in HIV incidence are similar to those in the CAB-LA only scenario: a 39% (23.4–55.9%) reduction in HIV incidence among PBW, a 26.5% (16.5–39.9%) reduction in postnatal vertical transmission, a 12.4% (7.4–16.8%) reduction in transmission at/before birth, and a 5.6%



Fig. 1. Impact and efficiency of promoting preexposure prophylaxis to pregnant and breastfeeding women. Bars represent the average from 1000 simulations; error bars represent the 2.5th and 97.5th percentiles of the model estimates. CAB-LA, cabotegravir (long-acting); PrEP, preexposure prophylaxis; PY, person-years.

(3.4–8.0%) reduction in total transmission. These are equivalent to 38 900 (22 500–56 300) infections averted in PBW, 9700 (5600–14 400) infections averted through breastfeeding, 2100 (1200–2900) infections averted at/before birth and 73 600 (42 900–106 700) infections averted in total.

The number of HIV infections averted per 100 additional person years of PrEP (relative to the base scenario) was greatest in the oral/CAB-LA choice scenario [1.21 (0.87–1.92)] and lowest in the oral PrEP-only scenario [0.79 (0.45–1.21)]. The most significant source of variation in this measure of efficiency is the uncertainty in the relative odds of PrEP uptake in low-risk women ($r = -0.77$; Figure S5, http://links.lww.com/QAD/D57).

Discussion

Although our previous modelling suggested that providing oral PrEP to PBW could reduce vertical transmission in South Africa by as much as 40%, as well as substantially reduce HIV incidence in women of reproductive age [8], our updated estimates suggest a more limited impact is likely. Our updated model has been parameterized using recent data from a PrEP cohort study conducted among pregnant and postpartum women in South Africa, which shows reasonable oral PrEP uptake but limited adherence and continuation [5,7,15]. In this context, CAB-LA could potentially be very important, reducing HIV incidence in PBW by around 40%, and reducing vertical transmission by around 24% – a reflection of both greater acceptability of injectable prevention methods [22–24] and superior efficacy [9]. Offering a choice of CAB-LA and oral PrEP would lead to the greatest PrEP uptake (consistent with the effect of choice in family planning [25]), but the impact on HIV transmission would not differ materially from offering CAB-LA alone.

Randomized controlled trials of PrEP have mostly excluded pregnant women, making it difficult to assess safety in this population [26]. Data on the safety of CAB-LA in PBW are being collected in the open-label extension of HPTN 084 [9], and early data show promise in terms of safety and pharmacology [13]. While we wait for CAB-LA to be provided as 'standard of care', consideration should be given to other strategies to boost oral PrEP adherence, for example, through real-time adherence feedback [6,27], SMS communication [28], and addressing mental health barriers to adherence [29].

Another concern about the rollout of CAB-LA is the potential for drug resistance. Breakthrough infections in individuals receiving CAB-LA might develop resistance to integrase strand transfer inhibitors (INSTIs), which would limit the effectiveness of dolutegravir, another INSTI widely used in HIV treatment. Although our model does not simulate INSTI resistance, other modelling studies suggest the benefits of CAB-LA (in terms of reducing AIDS mortality) are likely to far outweigh the risks, even if there is a substantial resistance risk [30].

Our estimates of population-level impact may underestimate impacts in other African settings, where fertility rates and breastfeeding durations are greater [31,32], or may over-estimate impacts in settings with relatively poor coverage of antenatal care [33]. Nevertheless, these results point to the importance of expanding PrEP options beyond the currently available oral PrEP, and of achieving better PrEP persistence and adherence, if HIV prevention benefits to women and their infants are to be maximized.

Acknowledgements

This research was funded by the National Institutes of Health (R01MH116771) and the Bill and Melinda Gates Foundation (019496).

D.J.D., L.M., and L.F.J. conceived the study. L.F.J. and L.J. developed the model and led the model parameterization. D.J.D. and S.D.M. contributed data and advised on parameterization. L.F.J. ran all analyses and drafted the article. All authors critically reviewed the manuscript and contributed to editing the article.

Conflicts of interest

There are no conflicts of interest.

References

1. Drake AL, Wagner A, Richardson B, John-Stewart G. **Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis.** *PLoS Med* 2014; **11**:e1001608.
2. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, *et al*. **The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV.** *J Acquir Immun Defic Syndr* 2012; **59**:417–425.
3. World Health Organization. WHO technical brief: preventing HIV during pregnancy and breastfeeding in the context of preexposure prophylaxis (PrEP). Geneva; 2017. Available at: http://apps.who.int/iris/bitstream/10665/255866/1/WHO-HIV-2017.09-eng.pdf. [Accessed 29 September 2017]
4. Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, *et al*. **Preexposure prophylaxis uptake and early continuation among pregnant and postpartum women within maternal and child health clinics in Kenya: results from an implementation programme.** *Lancet HIV* 2020; **7**:e38–e48.
5. Nyemba D, Mvududu R, Mashele N, Bekker LG, Gorbach P, Coates T, *et al*. Integrating PrEP into antenatal care for HIV-negative pregnant women in South Africa. In: *30th Conference on Retroviruses and Opportunistic Infections*. Seattle, USA; 2023.
6. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, *et al*. **PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial.** *PLoS Med* 2021; **18**:e1003670.
7. Joseph Davey D, Nyemba DC, Castillo-Mancilla J, Wiesner L, Norman J, Mvududu R, *et al*. **Adherence challenges with daily oral preexposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.** *J Int AIDS Soc* 2022; **25**:e26044.
8. Joseph Davey DL, Bekker LG, Gomba Y, Coates T, Myer L, Johnson LF. **Modelling the potential impact of providing pre-exposure prophylaxis in pregnant and breastfeeding women in South Africa.** *AIDS* 2019; **33**:1391–1395.
9. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, *et al*., HPTN 084 study group. **Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.** *Lancet* 2022; **399**:1779–1789.
10. Marzinke MA, Guo X, Hughes J, Hanscom B, Piwowar-Manning E, Hendrix C, *et al*. Cabotegravir pharmacology in the background of delayed injections in HPTN 084. In: *30th Conference on Retroviruses and Opportunistic Infections*. Seattle, USA; 2023.
11. Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, *et al*. **Relative cost-effectiveness of long-acting injectable cabotegravir versus oral preexposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.** *Lancet HIV* 2022; **9**:e857–e867.
12. Department of Health. 2021 updated guideline for the provision of oral preexposure prophylaxis (PrEP) to persons at substantial risk of HIV infection. 2021.
13. Delany-Moretlwe S, Hughes J, Guo X, Hanscom B, Hendrix CW, Farrior J, *et al*. Evaluation of CAB-LA safety and and PK in pregnant women in the blinded phase of HPTN 084. [Abstract 700]. *29th Conference on Retroviruses and Opportunistic Infections* [virtual]; 2022.
14. Haeri Mazanderani AF, Murray TY, Johnson LF, Ntloana M, Silere-Maqetseba T, Guo S, *et al*. **Eliminating vertical transmission of HIV in South Africa: establishing a baseline for the Global Alliance to end AIDS in children.** *Diagnostics (Basel)* 2023; **13**:2563.
15. Joseph Davey DL, Mvududu R, Mashele N, Lesosky M, Khadka N, Bekker LG, *et al*. **Early preexposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa.** *J Int AIDS Soc* 2022; **25**:e25866.
16. Jamieson L, Gomez GB, Rebe K, Brown B, Subedar H, Jenkins S, *et al*. **The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.** *AIDS* 2020; **34**:883–891.
17. Johnson LF, Dorrington RE. Thembisa version 4.6: A model for evaluating the impact of HIV/AIDS in South Africa. 2023. Available at: https://thembisa.org/downloads
18. Delany-Moretlwe S, Hanscom B, Angira F, Dadabhai S, Gadama D, Mirembe B, *et al*. Initial PrEP product choice: results from the HPTN 084 open-label extension [Abstract 5998]. In: *12th International AIDS Society Conference*. Brisbane; 2023.
19. Beksinska ME, Rees HV, Smit J. **Temporary discontinuation: a compliance issue in injectable users.** *Contraception* 2001; **64**:309–313.
20. Morroni C, Myer L, Mlobeli R, Gutin S, Grimsrud A. Dual protection among South African women and men: perspectives from HIV care, family planning and sexually transmitted infection services. Women's Health Research Unit, University of Cape Town; 2007. Available at: http://www.acquireproject.org/archive/files/6.0_integrate_fp-lapms/6.2_resources/6.2.2_studies/south_africa_dual_protection_final_report.pdf. [Accessed 10 July 2016]
21. Department of Health, Statistics South Africa, South African Medical Research Council, ICF. South Africa Demographic and Health Survey 2016. Pretoria; 2019. Available at: https://www.dhsprogram.com/pubs/pdf/FR337/FR337.pdf. [Accessed 19 March 2019]
22. Gill K, Happel AU, Pidwell T, Mendelsohn A, Duyver M, Johnson L, *et al*. **An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose).** *J Int AIDS Soc* 2020; **23**:e25626.
23. Wara NJ, Mvududu R, Marwa MM, Gomez L, Mashele N, Orrell C, *et al*. **Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya.** *J Int AIDS Soc* 2023; **26**:e26088.
24. Lorenzetti L, Dinh N, van der Straten A, Fonner V, Ridgeway K, Rodolph M, *et al*. **Systematic review of the values and preferences regarding the use of injectable preexposure prophylaxis to prevent HIV acquisition.** *J Int AIDS Soc* 2023; **26 (Suppl 2)**: e26107.
25. Ross J, Stover J. **Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009.** *Global Health Sci Pract* 2013; **1**:203–212.
26. Joseph Davey DL, Bekker LG, Bukusi EA, Chi BH, Delany-Moretlwe S, Goga A, *et al*. **Where are the pregnant and breastfeeding women in new preexposure prophylaxis trials? The imperative to overcome the evidence gap.** *Lancet HIV* 2022; **9**:e214–e222.
27. Joseph Davey DL, Dovel K, Mvududu R, Nyemba D, Mashele N, Bekker LG, *et al*. **Preexposure prophylaxis recent adherence with real-time adherence feedback and partner Human Immunodeficiency Virus self-testing: a pilot trial among postpartum women.** *Open Forum Infect Dis* 2022; **9**:ofab609.
28. Pintye J, Rogers Z, Kinuthia J, Mugwanya KK, Abuna F, Lagat H, *et al*. **Two-way short message service (SMS) communication may increase preexposure prophylaxis continuation and adherence among pregnant and postpartum women in Kenya.** *Global Health Sci Pract* 2020; **8**:55–67.
29. Stanton AM, O'Cleirigh C, Knight L, Joseph Davey DL, Myer L, Joska JA, *et al*. **The importance of assessing and addressing mental health barriers to PrEP use during pregnancy and postpartum in sub-Saharan Africa: state of the science and research priorities.** *J Int AIDS Soc* 2022; **25**:e26026.

30. Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, *et al*. **Predicted effects of the introduction of long-acting injectable cabotegravir preexposure prophylaxis in sub-Saharan Africa: a modelling study.** *Lancet HIV* 2023; **10**: e254–e265.
31. Bongaarts J. **Trends in fertility and fertility preferences in sub-Saharan Africa: the roles of education and family planning programs.** *Genus* 2020; **76**:32.
32. Glaubius R, Stover J, Johnson LF, Mahiane SG, Mahy MI, Eaton JW. **Differences in breastfeeding duration by maternal HIV status: a pooled analysis of nationally representative surveys in sub-Saharan Africa.** *J Acquir Immun Defic Syndr* 2024; **95**:S81-S88.
33. Arsenault C, Jordan K, Lee D, Dinsa G, Manzi F, Marchant T, Kruk ME. **Equity in antenatal care quality: an analysis of 91 national household surveys.** *Lancet Glob Health* 2018; **6**: e1186–e1195.
34. Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, Liu AY, *et al*. **Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.** *Lancet HIV* 2020; **7**: e472–e481.
35. Murchu EO, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, *et al*. **Oral preexposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.** *BMJ Open* 2022; **12**:e048478.
36. Donnell D, Gao F, Hughes JP, Hanscom B, Corey L, Cohen MS, *et al*. **Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.** *J Int AIDS Soc* 2023; **26**:e26118.
37. Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, *et al*. **Sexual behaviour of heterosexual men and women receiving antiretroviral preexposure prophylaxis for HIV prevention: a longitudinal analysis.** *Lancet Infect Dis* 2013; **13**:1021–1028.